Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung

Lung Cancer

Volumn 58, Issue 1, 2007, Pages 30-35

  Kozuki, Toshiyuki ^a   Hisamoto, Akiko ^a   Tabata, Masahiro ^a   Takigawa, Nagio ^a   Kiura, Katsuyuki ^a   Segawa, Yoshihiko ^b   Nakata, Masao ^b   Mandai, Koichi ^c   Eguchi, Kenji ^b   Ueoka, Hiroshi ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Adenocarcinoma; Atypical adenomatous hyperplasia; D761Y; Epidermal growth factor receptor (EGFR) mutation; Lung neoplasms; Multiple lesions

Indexed keywords

EPIDERMAL GROWTH FACTOR; GEFITINIB;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; EXON; FRAMESHIFT MUTATION; GENE DELETION; GENE FREQUENCY; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADENOCARCINOMA; ADENOMATOSIS, PULMONARY; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; GENES, ERBB-1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 34548509720     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.04.011     Document Type: Article

References (32)

1. Kleihues P., and Stewart B.W. Human cancers by organ site: lung cancer. In: Kleihues P., and Stewart B.W. (Eds). World Cancer Report (2003), IARC Press, Lyon, France 182-187
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
3. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20 (2002) 4285-4291
4. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21 (2003) 2237-2246
5. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
6. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
7. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
8. Tokumo M., Toyooka S., Kiura K., Shigematsu H., Tomii K., Aoe M., et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11 (2005) 1167-1173
9. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., and Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64 (2004) 8919-8923
10. Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10 (2004) 8195-8203
11. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346
12. Politi K., Zakowski M.F., Fan P.D., Schonfeld E.A., Pao W., and Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20 (2006) 1496-1510
13. Ji H., Li D., Chen L., Shimamura T., Kobayashi S., McNamara K., et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9 (2006) 485-495
14. Nakayama H., Noguchi M., Tsuchiya R., Kodama T., and Shimosato Y. Clonal growth of atypical adenomatous hyperplasia of the lung: cytofluorometric analysis of nuclear DNA content. Mod Pathol 3 (1990) 314-320
15. Yokozaki M., Kodama T., Yokose T., Matsumoto T., and Mukai K. Differentiation of atypical adenomatous hyperplasia of the lung by use of DNA ploidy and morphometric analysis. Mod Pathol 9 (1996) 1156-1164
16. Kerr K.M., Carey F.A., King G., and Lamb D. Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53 and c-erb-B2 expression. J Pathol 174 (1994) 249-256
17. Westra W.H., Baas I.O., Hruban R.H., Askin F.B., Wilson K., Offerhaus G.J., et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 56 (1996) 2224-2228
18. Cooper C.A., Carby F.A., Bubb V.J., Lamb D., Kerr K.M., and Wyllie A.H. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. J Pathol 18 (1997) 401-404
19. Travis W.D., Colby T.V., Corrin B., Shimosato Y., and Brambilla E. Histological typing of lung and pleural tumours. 3rd ed. (1999), Springer, New York
20. Noguchi M., and Shimosato Y. The development and progression of adenocarcinoma of the lung. In: Hansen H.H. (Ed). Lung Cancer (1995), Kluwer Academic Publishers, Boston 131-142
21. Suzuki K., Nagai K., Yoshida J., Yokose T., Kodama T., Takahashi K., et al. The prognosis of resected lung carcinoma associated with atypical adenomatous hyperplasia: a comparison of prognosis of well-differentiated adenocarcinoma associated with atypical adenomatous hyperplasia and intrapulmonary metastasis. Cancer 79 (1997) 1521-1526
22. Martini N., and Melamed M.R. Multiple primary lung cancers. J Thorac Cardiovasc Surg 70 (1975) 606-612
23. Yoshida Y., Shibata T., Kokubu A., Tsuta K., Matsuno Y., Kanai Y., et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer 50 (2005) 1-8
24. Haneda H., Sasaki H., Shimizu S., Endo K., Suzuki E., Yukiue H., et al. Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. Lung Cancer 52 (2006) 47-52
25. Yatabe Y., Kosaka T., Takahashi T., and Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29 (2005) 633-639
26. Inukai M., Toyooka S., Ito S., Asano H., Ichihara S., Ichihara S., et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66 (2006) 7854-7858
27. Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borras A.M., Gale C.M., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 116 (2006) 2695-2706
28. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352 (2005) 786-792
29. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73
30. Toyooka S., Kiura K., and Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N Engl Med J 352 (2005) 2136
31. Tokumo M., Toyooka S., Ichihara S., Ohashi K., Tsukuda K., Ichimura K., et al. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer 53 (2006) 117-121
32. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12 (2006) 6494-6501